330 related articles for article (PubMed ID: 12615653)
1. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.
Jeyakumar M; Thomas R; Elliot-Smith E; Smith DA; van der Spoel AC; d'Azzo A; Perry VH; Butters TD; Dwek RA; Platt FM
Brain; 2003 Apr; 126(Pt 4):974-87. PubMed ID: 12615653
[TBL] [Abstract][Full Text] [Related]
2. A possible biomarker of neurocytolysis in infantile gangliosidoses: aspartate transaminase.
Kılıç M; Kasapkara ÇS; Kılavuz S; Mungan NÖ; Biberoğlu G
Metab Brain Dis; 2019 Apr; 34(2):495-503. PubMed ID: 30712135
[TBL] [Abstract][Full Text] [Related]
3. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
Tsuji D
Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522
[TBL] [Abstract][Full Text] [Related]
4. Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: Volumetric quantitative MRI study.
Nestrasil I; Ahmed A; Utz JM; Rudser K; Whitley CB; Jarnes-Utz JR
Mol Genet Metab; 2018 Feb; 123(2):97-104. PubMed ID: 29352662
[TBL] [Abstract][Full Text] [Related]
5. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.
Huang JQ; Trasler JM; Igdoura S; Michaud J; Hanal N; Gravel RA
Hum Mol Genet; 1997 Oct; 6(11):1879-85. PubMed ID: 9302266
[TBL] [Abstract][Full Text] [Related]
6. Infantile gangliosidoses: Mapping a timeline of clinical changes.
Jarnes Utz JR; Kim S; King K; Ziegler R; Schema L; Redtree ES; Whitley CB
Mol Genet Metab; 2017 Jun; 121(2):170-179. PubMed ID: 28476546
[TBL] [Abstract][Full Text] [Related]
7. Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis.
Tsuji D; Akeboshi H; Matsuoka K; Yasuoka H; Miyasaki E; Kasahara Y; Kawashima I; Chiba Y; Jigami Y; Taki T; Sakuraba H; Itoh K
Ann Neurol; 2011 Apr; 69(4):691-701. PubMed ID: 21520232
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of central nervous system inflammation in infantile and juvenile gangliosidoses.
Utz JR; Crutcher T; Schneider J; Sorgen P; Whitley CB
Mol Genet Metab; 2015 Feb; 114(2):274-80. PubMed ID: 25557439
[TBL] [Abstract][Full Text] [Related]
9. GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies.
Leal AF; Benincore-Flórez E; Solano-Galarza D; Garzón Jaramillo RG; Echeverri-Peña OY; Suarez DA; Alméciga-Díaz CJ; Espejo-Mojica AJ
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867370
[TBL] [Abstract][Full Text] [Related]
10. Accumulation of lysosphingolipids in tissues from patients with GM1 and GM2 gangliosidoses.
Kobayashi T; Goto I; Okada S; Orii T; Ohno K; Nakano T
J Neurochem; 1992 Oct; 59(4):1452-8. PubMed ID: 1402895
[TBL] [Abstract][Full Text] [Related]
11. [GM2 gangliosidosis].
Tsuji S
Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):177-9. PubMed ID: 10434623
[No Abstract] [Full Text] [Related]
12. Western blotting analysis of the beta-hexosaminidase alpha- and beta-subunits in cultured fibroblasts from cases of various forms of GM2 gangliosidosis.
Utsumi K; Tsuji A; Kase R; Tanaka A; Tanaka T; Uyama E; Ozawa T; Sakuraba H; Komaba Y; Kawabe M; Iino Y; Katayama Y
Acta Neurol Scand; 2002 Jun; 105(6):427-30. PubMed ID: 12027830
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome assessments of disease burden and progression in late-onset GM2 gangliosidoses.
Kissell J; Rochmann C; Minini P; Eichler F; Stephen CD; Lau H; Toro C; Johnston JM; Krupnick R; Hamed A; Cox GF
Mol Genet Metab; 2024 Jul; 142(3):108512. PubMed ID: 38870773
[TBL] [Abstract][Full Text] [Related]
14. GM2 gangliosidosis variant B1 neuroradiological findings.
Grosso S; Farnetani MA; Berardi R; Margollicci M; Galluzzi P; Vivarelli R; Morgese G; Ballestri P
J Neurol; 2003 Jan; 250(1):17-21. PubMed ID: 12527987
[TBL] [Abstract][Full Text] [Related]
15. Neurophysiological investigations in GM1 and GM2 gangliosidoses.
Pampiglione G; Harden A
Neuropediatrics; 1984 Sep; 15 Suppl():74-84. PubMed ID: 6100798
[TBL] [Abstract][Full Text] [Related]
16. L-Arginine Ameliorates Defective Autophagy in GM2 Gangliosidoses by mTOR Modulation.
Castejón-Vega B; Rubio A; Pérez-Pulido AJ; Quiles JL; Lane JD; Fernández-Domínguez B; Cachón-González MB; Martín-Ruiz C; Sanz A; Cox TM; Alcocer-Gómez E; Cordero MD
Cells; 2021 Nov; 10(11):. PubMed ID: 34831346
[TBL] [Abstract][Full Text] [Related]
17. NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
Jeyakumar M; Smith DA; Williams IM; Borja MC; Neville DC; Butters TD; Dwek RA; Platt FM
Ann Neurol; 2004 Nov; 56(5):642-9. PubMed ID: 15505823
[TBL] [Abstract][Full Text] [Related]
18. Neuropathology of late onset gangliosidoses. A review.
Suzuki K
Dev Neurosci; 1991; 13(4-5):205-10. PubMed ID: 1817025
[TBL] [Abstract][Full Text] [Related]
19. Genetics and Therapies for GM2 Gangliosidosis.
Cachon-Gonzalez MB; Zaccariotto E; Cox TM
Curr Gene Ther; 2018; 18(2):68-89. PubMed ID: 29618308
[TBL] [Abstract][Full Text] [Related]
20. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.
Jeyakumar M; Butters TD; Cortina-Borja M; Hunnam V; Proia RL; Perry VH; Dwek RA; Platt FM
Proc Natl Acad Sci U S A; 1999 May; 96(11):6388-93. PubMed ID: 10339597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
